Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump
Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26.
Can-Fite’s Kickstarts Piclidenoson Study For Canine Osteoarthritis
Can-Fite BioPharma Ltd (NYSE: CANF) has
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd Announces Positive Data From Phase IIa Can-Fite NASH Study Published In Leading Peer Reviewed Scientific Journal
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary
Hope on the Horizon for Liver Cancer Patients as This Company’s Namodenoson Drug Starts Pivotal Phase III Global Trial
Photo by National Cancer Institute on Unsplash
Can-Fite Reports Completion Of Patient Enrollment In Phase 3 Psoriasis Study; Topline Results Expected In Q1’22
Positive interim analysis data was released in October 2020 based on results from 200 patients
Topline results expected Q1 2022
PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE:CANF)
The Week In Cannabis: $1.25B+ In Financings And M&A, Tilray, KushCo, New York And More
Below is a recap of the main news related to the cannabis industry and markets for the week of August 27, 2021.
Contents
Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY
Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.
The Daily Biotech Pulse: Priority Review For Amgen’s Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)
Aegis Capital Initiates Coverage On Can Fite Biofarma with Buy Rating, Announces Price Target of $5
Aegis Capital analyst Chrishan Anketell initiates coverage on Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Target of $5.